The debate about prescribing by brand or generic name has been a major issue for 40 years and it seems unlikely to wane, because of what has been termed the 'politics of prescribing'1. The issue is not as simple as is encapsulated in the quotation: 'There is everything in a name. A rose by any other name would smell as sweet, but would not cost half as much during the winter months.'
George Ade
This meeting of the Library (Scientific Research) Section was convened to examine some of the medical, marketing and regulatory aspects of innovative, and by implication patented, medicines and generic preparations.
Quality, safety and efficacy
The first speaker Dr Elliot Brown (Glaxo Group Research, Greenford) was given the difficult task of dealing with the quality, safety and efficacy of generic and proprietary medicines, perhaps because of his former experience with the Medicines Control Agency. He chose to confine his remarks largely to the situation in the United Kingdom, although he recognized, and referred to, the issue of generic substitution in the USA.
The issue of quality, safety and efficacy turns on the supposition that the original proprietary medicine sets the standard against which generic substitutes are compared. This is not an unreasonable premise since the research and development which determined the standard and which led to the original licence being granted would have been done with the innovative medicine. If one accepts the innovative medicine as having set the standard, the question can then be distilled into its three fractions: is the standard of the generic medicine adequate?; is it similar to the principal proprietary medicine?; and does comparability matter? If one accepts the principles ofthe Hippocratic Oath, and especially primum non nocere, then it is the third of these elements which is important.
The quality of a generic medicine is determined by the appropriate monograph in the British Pharmacopoeia, by the requirements of the Medicines Act and by EEC regulations. Specifications for the source and purity of starting materials, the route and method of synthesis, intermediate chemicals, formulations, limits of variation; stability and packaging are covered in these monographs and regulations. However, pharmacopoeial limits for control of substance and of impurities are not so narrow as to preclude some variability which might affect the clinical response, particularly if the therapeutic margin of the medicine is narrow.
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Medicines Control Agency has claimed that, based on reports of product defects, there is no difference in pharmaceutical quality between comparable branded and generic preparations. However, the quality of imported medicines depends on the mutual recognition of inspection procedures between regulatory bodies and on the analysis of imported samples and greater reassurances may be required for imported than for locally produced medicines.
The concept of an absolute standard for the quality of a medicine is, of course, artificial since there is often more than one branded version of a medicine as well as several generic forms. Therefore individual patients can receive anyone of a variety of preparations according to where their prescriptions are dispensed. To ensure that no problems arise when transfer between different versions of the same medicine occurs, relative quality is a necessary consideration. The interchangeability of medicines is essentially dependent on their bioequivalence which can be affected by differences in the physical characteristics of the compound, their method of manufacture, excipients and coatings, and variations in tablet compression. Such factors become critical with medicines having a narrow therapeutic ratio. In vitro testing of tablet disintegration and dissolution will provide reasonable evidence that a medicine is likely to be adequately absorbed. In vivo bioavailability studies are required where in vitro testing is likely to be inadequate or variable; where precision of dosage is important; where the compound is related to one with known bioavailability problems; where the properties of the compound make the process or formulation critical; for special coatings, additives, or processes; where the content of active ingredient is exceptionally low; and for potential interaction between additives. Bioavailability studies are usually done as double-blind, crossover studies in volunteers where the concentration of the active ingredient in the blood is measured at intervals. Bioequivalence is when the mean values for the area under the concentration/time curve (AUC) are within 20% of the reference mean AUC, or, in the USA, when the mean AUCs are within 25% in three-quarters of the subjects. Sometimes it is necessary to consider parameters other than the AUC, for example, with hypoglycaemic agents when speed of absorption is as important as the total amount absorbed. Some of the problems of methodology were discussed and the differences between healthy volunteers and patients were stressed.
The problems of biological inequality have been most noticeable with drugs for which the margin between efficacy and toxicity, the therapeutic index, is small, for example, the anticonvulsive agents. A 20% variation in the bioavailability of phenytoin, a drug with a narrow therapeutic margin and zero order kinetics, can mean the difference between inefficacy and toxicity. Breakthrough seizures have been reported when generic valproic acid, or carbamazepine, have been substituted for their respective branded versions and the Epilepsy Institute in New York has been reported as recommending that there should be no substitution of anti-epileptic drugs.
The American Pharmaceutical Manufacturers Association, in testimony to a Senate subcommittee, are reported to have given evidence of clinical problems through generic substitution with primidone, valproic acid, carbamazepine, tolazamide, chlorpropamide, propranolol and frusemide. However, the prevalence of clinical problems through general substitution with these medicines is not known, nor is the extent of unexpected hazards due to exposure to different additives and excipients through a change in formulation when a different preparation is substituted.
In effect, the extent of clinical problems of efficacy and safety arising from a change in preparations is not yet fully understood, although the existence of potential problems is recognized. In theory, there are many ways in which different formulations of the same active substance can differ but there is still a lack of objective evidence for substantial problems with the safety and efficacy of similar proprietary and generic preparations. Until rigorously evaluated evidence does become available, the question of the equivalence or otherwise of proprietary and generic preparations will remain unresolved and the topic is likely to be debated for some time to come, perhaps because of political and economic pressures.
Marketing and the future for medicines The controversial nature within the commercial pharmaceutical environment of generic medicines was acknowledged by the second speaker Dr Peter Forrester (Coopers & Lybrand Deloitte, London). The contentiousness is related to the subjectivity of the topic. Commercially, pharmaceuticals are the most profitable of all business sectors. There is a strong underlying demand for medicines which is related to the demographic shifts towards an ageing population in the major markets and there are many unmet needs. The traditional technologies are still bearing fruit, with new medicines continuing to be launched, and new technologies are beginning to be used for producing complex molecules such as human insulin. Information technology is also contributing to innovative medicines through computer modelling which reduces somewhat the risk inherent in basic chemical research. There are, of course, pressures on the pharmaceutical industry which will enforce change. The industry, like most others, is established on the discovery, development and distribution of 'products', although the products of the pharmaceutical industry happen to be medicines which are prescribed for the treatment of illness and the maintenance of health. For many reasons, the life cycles of the industry's products are becoming shorter and its costs are increasing but only three of the many influences were considered by the speaker. First, the reduction in average European prices; second, the expanding costs of research and development; third, measures to control the costs of medicines by national governments.
In comparing the pharmaceutical market in Europe in 1988 there were wide discrepancies in the prices of medicines, but probably not greater than those with cars and computers in the same countries. Parallel imports are a result of the price gradient between member states of the EEC and these account for 25%, or more, of the prescriptions written for some of the major products in the United Kingdom.
Expenditure on~esearch and development of new medicines has more than doubled in real terms over the past 10 years and it is still increasing at twice the rate of inflation.
Measures adopted by different European governments to control the costs of medicines vary and include generic substitution; monitoring doctors' prescribing costs; encouraging, or imposing, formularies; selectively reducing or withdrawing reimburse-ment of costs to patients; and increasing contributions made by patients towards the costs oftheir medicines.
Generic medicines become a serious threat to pharmaceutical innovation in those countries where substitution is obligatory, or positively encouraged, and where the unexpired patent term is so shortened by development requirements that the innovating company is unable to recoup its investment costs. The sales of a major product can fall by as much as 50% within 6 months of the expiry of a patent. The commercial impact of such events seems to have been a major influence in some of the recent mergers of major pharmaceutical companies. Thus, encouragement of generic prescribing can have a profound commercial impact on some pharmaceutical companies but it may also have little understood effects on the medicines bill for governments, as well as on investment and employment, although it is difficult to isolate the effects of a pro-generic policy from other pressures because they are interrelated.
Two ofthe issues which are connected with generic prescribing policies, through their effect on the life cycle of a product, are the unexpired patent term at the time of commercial introduction and price control measures. In Northern Europe patent protection on medicines has historically been strong, prices have been firm and generic products have become a growing business. In contrast, in Southern Europe traditionally patent production has been weak, prices have been relatively low and therefore the incentive for encouraging generic prescribing as a cost containment measure has been absent. It should be noted too that pharmaceutical companies in Southern Europe have also been less productive of innovative medicines.
Generic medicines and the single European market Mr Steven Stocks (Chairman of the British Generic
Manufacturers Association and General Manager of Approved Prescription Services) was asked to deal with the regulatory implications for generic medicines of the single European market of 1992, although he disclaimed any specialist knowledge of regulatory affairs. Therefore, he chose to broaden the coverage of his talk to include patent life extension, original pack dispensing and price harmonization.
Starting in 1965, a flow of EEC Directives has increased the regulatory burden on the licensing of medicines. After the establishment of multistate applications, the key issue for generic medicines has been the introduction, in 1987, of abridged licensing applications. This allows companies which produce generic medicines to apply for licences without the burden of carrying out clinical trials and compiling complete clinical dossiers. Another effect of the EEC Directives has been gradually to reduce, over the past 20 years, the differences in the regulatory requirements for medicines between the different European countries. Although the licensing requirements are not identical throughout the EEC, they have become similar.
The multistate application requires that an application, whether full or abridged, be submitted to a national regulatory body in one of the EEC countries; this is not required to be the one in the country of the applicant. Ifthe application is approved, the national regulatory body submits a summarized assessment Journal of the Royal Society of Medicine Volume 84 June 1991 377 of the application to other European regulatory authorities. If this summary is rejected by another European regulatory authority, that authority makes its own assessment and sends it to the CPMP (Committee on Proprietary Medicinal Products). If the CPMP accepts the summary, it is intended that approval of the licence becomes binding throughout the EEC. It is proposed that this procedure will eventually be superseded by a single application to a European Medicines Control Agency. A summary document and assessment will be prepared and sent to the CPMP and, if these are accepted, the EEC Commission will be advised and will issue a draft notice of approval of the application to national authorities in Europe.
Patents applied to medicines are not as simple as is sometimes imagined. The early patent usually applies to a series of related compounds but rarely does this patent cover the innovative medicine which eventually emerges as the commercial preparation. This is covered by a product patent. Sometimes the life of this original patent can be extended by modifying the synthetic route of production with a new patentable process. To circumvent this extension of the life of a patent, a generic company would have to prepare its generic version of the patented preparation, after expiry of the product patent, from material produced by a process that did not infringe the process patent. In these circumstances, because of the inevitable differences between the raw materials in the proprietary and generic versions, an abridged licence application is unlikely to be acceptable. By 1985 the effective life of a product patent had been reduced to an average of 8 years. The so-called 10-year rule has reversed this trend in reduction of the effective patent life by returning it to the levels applicable in 1980. The intention of the proposed supplementary protection certificate will be to restore the effective patent life to about 16 years and return the situation to what it was in the early 1970s. According to Mr Stocks, the British Generic Manufacturers Association supports this proposal to extend the effective patent life as a means of maintaining a healthy pharmaceutical industry.
The United Kingdom shares the distinction with Nigeria of dispensing prescription medicines mainly from bulk containers; most European countries issue original packs from the manufacturers. However, a proposed EEC directive due to be implemented by January 1992, although the parallel draft UK legislation specifies January 1993, will require substantial information for patients to be issued with dispensed medicines. It is difficult to envisage how this can be done other than by original pack dispensing (OPD) for all prescribed medicines, including generics, so that a patient information leaflet can be included with the pack. The pressures of consumer protection and product liability are encouraging OPD and manufacturers, who go to great lengths to ensure the quality and integrity of their products, also feel more comfortable with OPD. Legislation is required not only to introduce OPD in the United Kingdom, but also to reimburse pharmacists for the costs of OPD and for issuing quantities in the original pack which are not identical with those on the prescription.
The price differential between proprietary and generic medicines is likely to narrow because of the pressures of cost containment on the innovators to reduce their prices and the increased costs of licensing and OPD on generic manufacturers causing their prices to increase. This, and the harmonization of prices across Europe will probably eliminate parallel importing.
Afterword
The use ofthe word versus in the title of this meeting might have led one to expect two opposing views from the protagonists of innovative and generic medicines with perhaps the third speaker taking a neutral, or independent, stance. In the event, there was no adversarial encounter; instead there was remarkable unanimity. Perhaps the abiding impression was one of external forces acting on the pharmaceutical Sudden or unexpected deaths Keywords: sudden infant death syndrome; certification; gaseous deaths; homicide
The Section of Clinical Forensic Medicine has now entered its fourth year and an increasing membership including representatives from other branches of medicine and from other disciplines has ensured not only its survival but its continued and successful involvement in the activities of the Royal Society of Medicine.
It is the policy of the Section to select as themes for major meetings topics which are of general interest and importance to all who are interested in the legal implications of medical practice as well as to those whose prime interest is in Clinical Forensic Medicine. Accordingly, the entire morning of the meeting on the 13 October 1990 was devoted to papers on 'Sudden Unexpected Death'.
Sudden infant death syndrome, otherwise known as cot death is a problem which has been a source of great anxiety to forensic medical examiners, to paediatricians, to family doctors and of course to parents -not only to those who themselves have been bereaved, but also to those who are aware of the existence and fear that their children may become victims. It was fitting therefore that it should be taken as the subject of our first paper of the day. The speaker was Dr Robert Chambers (Barrister and Coroner for the Inner London North District) who for the past 20 years has taken an interest in, and played an active part in the study of prevalence and possible causation of sudden infant death syndrome. He reviewed early work carried out in Seattle and in Cambridge and questioned the validity ofthe generally accepted definition, namely 'The sudden death of any infant which is unexpected, and where there is no history, and where thorough postmortem shows no adequate evidence as to the cause of death'. Dr Chambers posed the question 'How thorough is thorough, did it include histology, and how adequate is adequate?' In the 1970s Camps and others took a fresh look at sudden infant death syndrome and Camps proposed to Dr Chambers manufacturers, both innovative and generic, so that neither was in control of its own destiny; both will need to adapt in order to survive. One was constantly reminded of the Second Order Rule of Bureaucracy: 'The more directives you issue to solve a problem, the worse it gets'", P J Keen Editorial Representative Library (Scientific Research) Section a pilot study involving the deaths of children under the age of 2 years in four London Boroughs. This study and the subsequent changes in attitude and of methods of investigation showed that in a high proportion of cases of sudden death in children a careful examination of the history demonstrates that the child had well defined symptoms prior to death and that in some, postmortem showed well defined evidence of pneumonia. It was found that there had been clinical evidence in the days preceding death and that in some cases the care given to the child had not been totally adequate. As a result of better care and awareness there has been a steady reduction in the number of cot deaths since the 1970s, but there remains a residue of babies, apparently healthy and well cared for by their parents, who do die, and in whom there is still no demonstrable cause. Cot Death Research and Support Newsletter of August 1990 acknowledges the reduction in deaths but advises caution pointing out that there is a variation in the method of gathering and interpretation of statistical information in different districts and regions. Dr Chambers expressed the hope that the recommendation that every Regional Health Authority should have a paediatric pathologist in post by April 1991 will be fulfilled. Dr Chambers concluded his presentation with a review of some of the recent theories which emphasize the importance of simple observation by those dealing with children, for example, variations in weight, reaction to different environments and temperature control. The trend towards improvement is encouraging but clearly there is still a great deal of work to be done before the problem of sudden infant death syndrome will be solved.
It is generally recognized that undergraduate teaching of medical jurisprudence ranges with a few notable exceptions, from the barely adequate to the totally inadequate;' stories abound of the inability of newly qualified doctors to complete accurately Death and Cremation Certificates, to understand his or her responsibilities to the Coroner and indeed those to the patient. It was fitting therefore that the second paper of the morning session should be entitled 'Problems of Death Certification'. It was presented by Dr P K Schutte, Assistant Secretary of the Medical Defence Union.
